The AI tool is designed to help cardiologists detect rare and chronic cardiovascular diseases. Credit: Antonio Marca / Shutterstock.

Canadian health technology company WELL Health Technologies has introduced an AI-powered ‘co-pilot’ designed to help cardiologists identify patients at increased risk of cardiovascular diseases (CVDs).

The AI tool was developed jointly by WELL Health and its investee, HEALWELL AI, a company specialising in AI and data science for preventative care.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It is an advancement of WELL’s AI capabilities following the launch of its second-generation AI-powered physician co-pilot, WELL AI Decision Support (WAIDS), which was also created in exclusive partnership with HEALWELL.

The new HEALWELL AI-powered technology will be implemented across WELL Diagnostics Centres’ network of cardiology and medical diagnostic facilities in Canada, which includes more than 40 sites in Ontario.

WELL Diagnostic Centres CEO Dina Sergi said: “The integration of HEALWELL’s AI-powered co-pilot for cardiologists into our WELL Diagnostic Centres represents a game-changing advancement.

“By offering precise risk stratification and actionable insights, this tool enhances their ability to proactively manage cardiovascular health and improve patient care.” 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CVDs encompass a variety of heart and blood vessel disorders and are the world’s leading cause of death, accounting for around 32% of global deaths in 2019, according to the World Health Organization.

They are the third leading cause of mortality in Canada, making the early identification of deteriorating cardiovascular conditions a critical healthcare priority.

HEALWELL said it expects the technology to expedite life science research and development related to CVD, as well as create business opportunities for BioPharma Services, a clinical research organisation that was recently acquired by HEALWELL.

HEALWELL CEO Dr Alexander Dobranowski said: “The integration of this tool into WELL’s Diagnostic Centres is particularly important, as it provides us access to Canada’s largest cardiology group.

“This vast dataset not only assists hundreds of cardiologists within the WELL Diagnostic Centres ecosystem but also allows us to continuously refine and enhance the co-pilot.”